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Despite several studies regarding the correla-
tion between serum HBsAg titers and viral
loads, the association remains uncertain.
Eighty-nine individuals were selected randomly
from a Chinese cohort of 2,258 subjects infected
persistently with hepatitis B virus (HBV) for
cross-sectional and longitudinal analysis. Viral
loads of mutant HBV are lower than those of
wild type HBV. The serum HBsAg titers corre-
late positively with viral loads in both HBeAg
positive and negative subjects (r¼ 0.449,
P¼ 0.013; r¼ 0.300, P¼ 0.018, respectively). No
correlation between serum HBsAg titer and
viral loads was found in any of the four phases
of chronic HBV infection. The serum HBsAg
titers correlate positively with viral loads in the
group with wild type sequences of the PreS/S,
basal core promoter (BCP), and preC regions of
HBV(r¼ 0.502, P¼ 0.040). However, the correla-
tion was not seen in the group with mutations
in these regions (r¼ 0.165, P¼ 0.257). The corre-
lation between HBsAg titers and viral loads was
seen in individuals with wild type PreS/S
sequences but not in the subgroup with BCP
double mutations or PreC stop mutation,
although their sequences in the preS/S regions
were wild type. All these findings were con-
firmed by the longitudinal analysis. In conclu-
sion, the correlation between serum HBsAg
levels and viral loads may not differ between
HBeAg positive and negative individuals but
may depend on wild-type or mutated genomic
sequences. Therefore, HBsAg quantitation may
be used as a surrogate for viral loads in only
wild-type HBV infections. J. Med. Virol.
87:1351–1360, 2015.
# 2015 Wiley Periodicals, Inc.
KEY WORDS: hepatitis B virus; HBsAg; muta-
tions; correlation; viral loads
INTRODUCTION
Hepatitis B virus (HBV) has a circular, partially
double-stranded DNA genome of about 3200 nucleo-
tides with four open reading frames (ORFs), namely
the precore/core, polymerase, surface, and X ORFs
[Tiollais et al., 1985]. Monitoring the serum concen-
trations of HBV DNA has been used to predict the
outcome of chronic HBV infection and the response to
antiviral therapy [Yuen et al., 2007; Yuen et al.,
2009]. However, HBV DNA quantification remains
expensive and, more importantly, it is not easily
accessible or affordable in developing counties where
HBV infection is prevalent [Su et al., 2010].
Hepatitis B surface antigen (HBsAg) was the first
HBV protein discovered in 1965 [Blumberg et al.,
1965]. The HBsAg found in serum can include all
three forms of the surface protein found in the
mature HBV virion, the large (L), medium (M), and
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small (S) proteins. These proteins are encoded by the
S-ORF which contains three, in-frame initiation
codons and is divided into the Pre-S1, Pre-S2 and S
domains [Locarnini and Bowden, 2012]. Over the
years, detection of HBsAg in serum has been the
hallmark of HBV infection and remains the corner-
stone for the diagnosis of acute and chronic hepatitis
B [Martinot-Peignoux et al., 2014]. HBsAg quantifica-
tion has been recognized as valuable for monitoring
the natural history of chronic hepatitis and predict-
ing treatment outcome [Martinot-Peignoux et al.,
2013]. Compared to HBV DNA, quantification of
HBsAg is relatively inexpensive and has been used
widely.
Since the first report in 2004 of a positive correla-
tion between the serum HBsAg titer and HBV DNA
concentrations [Deguchi et al., 2004], several studies
have yielded similar results [Gupta et al., 2012;
Alghamdi et al., 2013; Suh et al., 2014] and suggested
that the serum HBsAg titer may be used as a
surrogate marker of serum HBV DNA in chronic
HBV infection [Su et al., 2010; Sun et al., 2012].
However, at the same time, there are some contra-
dicting results from other studies suggesting that
quantitative HBsAg assays cannot substitute for
HBV DNA quantification [Kuhns et al., 2004; Wie-
gand et al., 2008; Ganji et al., 2011]. Although a
further study suggested that the correlation between
quantitative HBsAg titers and serum HBV DNA
differs between HBeAg-positive and HBeAg-negative
patients with chronic hepatitis B (CHB) [Thompson
et al., 2010], the contradictory results remain unex-
plained. Some studies found the correlation in
HBeAg-positive CHB patients [Su et al., 2010, 2012;
Suh et al., 2014] while others found the correlation in
HBeAg-negative CHB patients [Seto et al., 2012;
Alghamdi et al., 2013].
The high rate of viral replication, combined with
an error-prone polymerase, results in a very high
frequency of mutational events during HBV infection.
The most commonly mutations are the preC stop
mutation (G1896A) that prevents the synthesis of
HBeAg, BCP double mutations (A1762T, G1764A),
and PreS mutations [Harrison, 2006]. It has been
reported that BCP double mutations and preS
mutations have an impact on HBV replication [Buck-
wold et al., 1996; Bock et al., 1997; Kondo et al.,
2002]. Recently, a cross-sectional analysis showed
that the correlation between serum HBsAg titers
and HBV DNA concentrations differs between wild
type and mutated preS/S sequences. However, the
authors did not report an analysis according to the
sequence status of the BCP and preC [Pollicino et al.,
2012].
In this study, a cross-sectional analysis was
carried out to determine the correlation between
serum HBsAg titers and HBV DNA concentrations,
according to the sequence status of HBV, and
included a longitudinal analysis to test this correla-
tion further.
MATERIALS AND METHODS
Study Subjects and Sample Design
The study subjects were recruited from the Long
An cohort, which has been described previously
[Fang et al., 2008]. The cohort was recruited in early
2004 from agricultural workers aged 30–55 living in
the rural area of Long An county, Guangxi, China,
using stratified sampling. We started to follow up the
study subjects from 1st July, 2004. Each study
subject provided a serum sample every six months
for the assessment of virological parameters and AFP
concentrations. In this study, the study subjects were
selected from the first to third round follow-up
according to the availability of serum for quantifica-
tion of HBsAg, measurement of viral loads and HBV
DNA sequencing, and their HBeAg/anti-HBe status
was stable (at least for the period covering the three
tests).
Informed consent in writing was obtained from
each individual. The study protocol conforms to the
ethical guidelines of the 1975 Declaration of Helsinki
and has been approved by the Guangxi Institutional
Review Board.
Serological Testing
Sera were tested for HBsAg and HBeAg/anti-HBe
using enzyme immunoassays (Zhong Shan Biological
Technology Company, Limited, Guangzhou, China).
Alanine aminotransferase (ALT) levels were deter-
mined using a Reitman kit (Sichuan Mike Scientific
Technology Company, Limited, Chengdu, China).
HBsAg Measurement
Serum HBsAg titers were measured by a commer-
cial chemiluminescent microparticle immunoassay
using the ARCHITECT i2000SR platform and Abbott
Architect HBsAg reagents (Abbott Ireland Diagnos-
tics Division, Finisklin Business Park, Sligo, Ireland)
with a dynamic range of 0.05-250 IU/ml. In cases
where the HBsAg titers were >250 IU/ml, serial
1:500 dilutions were performed according to the
manufacturer’s instructions.
Nested PCR for HBV DNA and Nucleotide
Sequencing
DNA was extracted from 85ml serum by pronase
digestion followed by phenol/chloroform extraction.
To amplify the preS/S region, the first round poly-
merase chain reaction (PCR) was carried out in a
50ml reaction using primers LSOB1 (nt 2739-2762,
50-GGCATTATTTGCATACCCTTTGG-30) and MDN5R
(nt1794-1774, 50-ATTTATGCCTACAGCCTCCT-30)
with 5min hot start, followed by 30 cycles of 94˚C for
30 sec, 50˚C for 30 sec, and 72˚C for 90 sec. Second
round PCR was carried out on 5ml of the first round
products in a 50ml reaction using primers LSBI1 (nt
2809-2829, 50-TTGTGGGTCACCATATTCTT-30) and
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HCO2 (nt 761-776, 50-GCGAAGCTTGCTGTACA-
GACTTGG- 30) and the same amplification protocol
as first round.
To amplify the preC/BCP region, the first round
PCR was carried out in a 50ml reaction using primers
B935 (nt 1240–1260, 50-AACCTTTGTGGCTCCTCTG-
30) and MDC1 (nt 2304–2324, 50-TTGATAAGA-
TAGGGGCATTTG-30), with 5min hot start followed
by 30 cycles of 94˚C for 30 sec, 50˚C for 30 sec, and
72˚C for 90 sec. Second round PCR was carried out on
5ml of the first round product in a 50ml reaction
using primers CPRF1 (nt 1678–1695, 50-CAATGT-
CAACGACCGACC-30) and CPRR1 (nt 1928–1948,
50-GAGTAACTCCACAGTAGCTCC-30) and 5min
hot start, then 30 cycles of 94˚C for 30 sec, 55˚C for
30 sec, and 72˚C for 30 sec.
HBV DNA positive products were sent to The
Sangon Biotech (Shanghai, China) for sequencing
using a BigDye Terminator V3.1 Cycle Sequencing
kit (Applied Biosystems, Foster City, CA) with
sequencing primer LSBI1 and HCO2 for the preS/S
sequence and CPRF1for the BCP/precore sequence.
Measurement of Viral Loads
Serum HBV DNA concentrations were quantified
by real time PCR using commercial reagents (Shang-
hai ZJ Bio-Tech Co., Ltd. (Shanghai, China)) in an
ABI Prism 7500 sequence detection system (Applied
Biosystems) with a dynamic range of 24.4–109 IU/ml,
using HBV primers and a dual labeled TaqMan
probe, as described previously [Fang et al., 2009].
HBV Genotyping
HBV genotypes were determined using the sequen-
ces of the S ORF and the STAR program [http://www.
vgb.ucl.ac.uk/starn.shtml] [Myers et al., 2006] and
the NCBI Genotyping Tool (http://www.ncbi.nlm.nih.
gov/projects/genotyping/formpage.cgi).
Statistical Analysis
The data are presented as median (range) and as
numbers with percentages as appropriate, unless
otherwise stated. Continuous and categorical varia-
bles were compared between groups using, respec-
tively, the Mann-Whitney test and the chi-square/
Fisher’s exact test. Pearson’s correlation coefficient
(r) was used to describe the correlation between two
continuous, normally distributed variables. Spear-
man’s correlation was used where variables were not
distributed normally. Simple and multiple linear
regression analyses were performed to identify inde-
pendent factors for serum HBsAg titer quantification.
For the regression analyses, a logarithmic transfor-
mation was applied to all viral load and HBsAg
measurements prior to analysis to achieve an approx-
imately normal distribution. All P-values were two-
tailed and P< 0.05 was considered to be significant.
All statistical analyses were performed using the
SPSS software (ver.16.0; Chicago, IL).
RESULTS
Baseline Characteristics
Eighty-nine study subjects were recruited from the
Long An cohort, 52 males and 37 females. The mean
ages were 37.5 6.2 years. Twenty four (27%) study
subjects were HBeAg-positive and 65 (73%) were
HBeAg-negative. There are 23 samples with one of
following mutations, PreS deletions or preS2 initia-
tion codon mutation, BCP double mutations
(T1762A1764), and preC stop mutation (nt1896), 24
samples with two of these mutations, and five
samples with all of these mutations. In additional,
there are 17 samples without any of these mutations.
Therefore, there are 52 samples with mutated se-
quences. Overall, 25.8% of the study subjects had
abnormal ALT levels (>40 IU/ml). No stop mutation
in the S gene or amino acids changes in the “a”
determinant of HBsAg was found. Three genotypes
were identified, B, C, and I, with a prevalence of
64%, 30.3%, and 5.6% respectively. The distribution
of serum HBsAg titer across the study subjects was
skewed (Fig.1); most (61.6%) had HBsAg titers below
5000 IU/ml. The median (range) of HBsAg is 2.9 103
(IU/ml) (5.0 101–4.6 105). The median (range) of
viral loads is 3.0 105 (IU/ml) (5 102–4.8 108)
(Table I).
Distribution of Serum HBV DNA Concentrations
Between Wild Type and Mutated HBV Sequences
The viral loads of individuals with wild type
sequences in the PreC and BCP regions are signifi-
cantly higher than of those with mutations in these
regions. Data from the follow up samples were
consistent with this finding. Although the difference
in viral loads between the PreS/S wild type group
and mutation group in the first and third round
samples is not significant, that in the second round is
on the border of significance (Table II). These results
suggest that, in most cases, viral loads of mutant
HBV are lower than those of wild type HBV.
The Correlation Between HBsAg Titers and
Serum HBV DNA Concentrations According
to the HBeAg Status
In the first round of follow up, the serum HBsAg
titer in total was positively correlated with serum
HBV DNA (r¼ 0.642, P< 0.001) and this positive
correlation was seen in both HBeAg positive and
negative subjects (r¼ 0.449, P¼ 0.013; r¼ 0.300,
P¼ 0.018, respectively) (Fig. 2A and D). The correla-
tion could also be seen in the third round samples
(r¼ 0.782, P< 0.001for HBeAg positive group;
r¼ 0.279, P¼ 0.028 for the HBeAg negative group,
respectively) (Fig. 2C and F). In the second round
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samples, the correlation was only seen in the HBeAg
positive group (Fig. 2B) and not in HBeAg negative
group (r¼ 0.229, P¼ 0.078) (Fig. 2E). However, the
P-value is close to significance. These findings sug-
gest that the correlation between serum HBsAg levels
and viral loads may not differ between HBeAg
positive and negative individuals.
The Correlation Between HBsAg Titers and
Serum HBV DNA Concentrations According to
Phases of Chronic HBV Infection
Chronic HBV infection has a complicated course
and four phases have been described: immune toler-
ant, immune clearance, inactive and immune escape
phase [Brooks et al., 2013]. The correlation between
serum HBsAg titers and HBV DNA concentrations
was examined for each phase. No correlation was
found in any of the four phases (n¼ 19, r¼ 0.423,
P¼ 0.071; n¼ 5, r¼ 0.838, P¼ 0.077; n¼ 45, r¼ 0.242,
P¼ 0.110 and n¼ 17, r¼ 0.421, P¼ 0.092,
respectively).
The Correlation Between HBsAg Titers and
Serum HBV DNA Concentrations According to
PreS/S, BCP, and PreC Sequence Status
The serum HBsAg titers were positively correlated
with serum HBV DNA concentrations in the first
round samples from the groups with wild type preS/
Fig. 1. Distribution of serum HBsAg titers. The number of individuals in different ranges of
HBsAg titer. The distribution of serum HBsAg titer across the study subjects is skewed.
TABLE I. Characteristics of Subjects According to the Status of HBeAg
Characteristics All subjects HBeAg (þ) HBeAg () P
N 89 24 65
Age, years, mean (SDa) 37.5 (6.2) 36.2 (5.8) 37.9 (6.3) 0.220
Male sex, n (%) 52 (58.4) 16 (18) 36 (40.4) 0.338
HBV genotypes, n (%) 0.679
B 57 (64) 16 (66.7) 41 (63.1)
C 27 (30.3) 6 (25.0) 21 (32.3)
I 5 (5.6) 2 (8.3) 3 (4.6)
HBV DNA,I U/ml,
median (range)
3.0105
(5 102-4.8108)
1.5108
(1.9 106-4.8108)
7.6104
(5102-5.9107)
0.000
HBsAg, IU/ml,
median (range)
2.9103
(5.0101-4.6 105)
4.5104
(7.6 102-4.6105)
2.4103
(5101-5.6104)
0.000
Abnormal ALTb, n (%) 23 (25.8) 5 (5.6) 18 (20.2) 0.512
T1762A1764 mutations, n (%) 38 (42.7) 3 (3.4) 35 (39.3) 0.000
PreS deletion or PreS2
start codon mutations
27 (30.3) 5 (5.6) 22 (24.7) 0.236
PreC stop mutation, n (%) 32 (46.4, 32/69) 0 32 (46.4, 32/37) 0.000
aSD, standard deviation.
bALT, alanine aminotransferase.
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Fig. 2. The correlation between serum HBsAg titers and HBV DNA concentrations according
to the HBeAg status. Correlation between serum HBsAg titers and HBV DNA concentrations in
HBeAg positive individuals in the first (A), second (B) and third (C) round samples and in
HBeAg negative individuals in the first (D), second (E) and third (F) round samples.
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Fig. 3. The correlation between HBsAg titers and serum HBV DNA concentrations according
to the sequence status. Correlation between serum HBsAg titers and HBV DNA concentrations
in individuals with wild type sequences in the first (A), second (B) and third (C) round samples
and in those with mutated sequences in the first (D), second (E) and third (F) round samples.
Mutations included preS deletions and mutations in the preS2 initiation codon, basal core
promoter double mutations (T1762A1764) and preC stop mutation (nt1896).
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S, BCP and PreC sequences (r¼ 0.502, P¼ 0.040)
(Fig. 3A). However, the correlation was not seen in
the first round samples from the groups with mu-
tated sequences, including PreS deletions or preS2
initiation codon mutation, BCP double mutations
(T1762A1764) and preC stop mutation (nt1896)
(r¼ 0.165, P¼ 0.257) (Fig. 3D). In order to confirm
these findings, data from second and third rounds of
follow-up were analyzed. Again, the serum HBsAg
titers were also positively correlated with serum HBV
DNA concentrations in the groups with wild type
preS/S, PreC and BCP sequences (r¼ 0.553,
P¼ 0.026; r¼ 0.671, P¼ 0.004, respectively) (Fig. 3B
and C) but not in the groups with mutated sequences
(r¼ 0.148, P¼ 320; r¼ 0.220, P¼ 0.125, respectively)
(Fig. 3E and F). These findings suggest that the
correlation between serum HBsAg levels and viral
loads differs between individuals with wild type and
mutated HBV sequences. Therefore, HBsAg quantita-
tion could be used as a surrogate for viral load in
wild-type infections only.
It has been reported that there is a correlation
between HBsAg and viremia levels in individuals
infected with HBV with wild type preS/S sequences
[Pollicino et al., 2012]. We carried out an analysis of
those individuals with wild type preS/S sequences
and also found the correlation in the first, second and
third round samples (n¼ 59, r¼ 0.780, P< 0.001;
n¼ 58, r¼ 0.715, P< 0.001; n¼ 58, r¼ 0.751,
P< 0.001, respectively). Meanwhile, subgroups with
BCP double mutations or PreC stop mutation were
selected from those infected with wild type preS/S
sequences for a stratification analysis. No correlation
was found between HBsAg and viremia levels in the
first, second and third round samples with BCP
double mutations (n¼ 23, r¼ 0.362, P¼ 0.090; n¼ 23,
r¼ 0.116, P¼ 0.599; n¼ 22, r¼ 0.172, P¼ 0.443, re-
spectively) or PreC stop mutation (n¼ 16, r¼ 0.494,
P¼ 0.052; n¼ 17, r¼ 0.420, P¼ 0.093; n¼ 18,
r¼ 0.340, P¼ 0.167, respectively).
In order to eliminate the confounding effect of
other mutations on the correlation between HBsAg
and viremia levels, a further stratification analysis of
individuals with BCP double mutations (T1762A1764)
or preC stop mutation (nt1896) only was performed.
Again, no correlation between serum HBsAg titer
and viral loads was found in any round samples from
those with BCP double mutations (n¼ 10,r¼0.334,
P¼ 0.346; n¼ 9, r¼ 0.202, P¼ 0.602; n¼ 10, r¼ 0.489,
P¼ 0.151, respectively) or preC stop mutation (n¼ 9,
r¼ 0.487, P¼ 0.193; n¼ 9, r¼ 0.517, P¼ 0.154; n¼ 10,
r¼ 0.594, P¼ 0.070, respectively), suggesting that the
correlation between serum HBsAg levels and viral
loads varies according to the sequence status of preS/
S, BCP, and preC.
Analysis for Factors Associated With
HBsAg Titers
Simple and multiple linear regression analyses
were used to identify the factors that affect the titer
of serum HBsAg. The independent variables included
HBV DNA concentrations, HBeAg, gender, age, ALT,
genotypes, BCP double mutations, PreC stop muta-
tion, and PreS/S mutations (deletions and PreS2
initiation codon mutations). In the simple linear
regression analysis, HBV DNA concentrations,
HBeAg status, BCP double mutations, and PreC stop
mutation were found to affect the titer of serum
HBsAg. However, in the multiple linear regression
analysis, sex, HBV DNA concentrations, and HBeAg
status were found to affect significantly the levels of
serum HBsAg. HBV sequence mutations (PreS/S
mutations, BCP and PreC) did not affect the serum
HBsAg titer (Table III).
DISCUSSION
The principal findings of this study are that the
correlation between serum HBsAg levels and viral
loads varies according to wild type and mutated HBV
sequences. The correlation between serum HBsAg
levels and viral loads may not differ between HBeAg
positive and negative individuals or among the
phases of chronic HBV infection. Viral loads of
mutant HBV are usually lower than those of the wild
type. HBV DNA concentrations and HBeAg status
significantly affect the levels of serum HBsAg. The
strength of this study is that the results of cross-
sectional analysis are supported by the results of
longitudinal analysis, which overcomes the
TABLE II. Distribution of Serum HBV DNA Levels Between Wild Type and Mutated Sequences of HBV
First round Second round Third round
Sequence status
Median
IU/ml P-value
Median
IU/ml P-value
Median
IU/ml P-value
PreS/S wild type 2.095105 0.675 2.455 105 0.047 2.16 105 0.328
PreS/S mutant 5.51 105 9.01103 2.355105
BCP wild type 5.36 106 0.002 5.52105 0.011 8.1 x 105 0.01
BCP mutant 1.009105 1.86104 9.045104
PreC wild type 9.0106 0.001 2.56106 0.001 4.58 106 0.001
PreC mutant 7.215104 5.1 103 2.255104
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deficiencies associated with fluctuations of HBsAg. A
weakness of the study is that the results were
obtained for genotypes B and C and it is unclear
whether they hold true for other genotypes.
There have been many studies of the correlation
between serum HBsAg titer and HBV DNA but,
unfortunately, the results are contradictory [Wiegand
et al., 2008; Su et al., 2010; Ganji et al., 2011; Sun
et al., 2012; Suh et al., 2014]. Although some studies
suggested that the correlation between quantitative
HBsAg titers and serum HBV DNA concentrations
differs between patients with HBeAg-positive and
HBeAg-negative CHB [Thompson et al., 2010], this
finding was not confirmed by others [Su et al., 2010;
Sun et al., 2012; Seto et al., 2012; Alghamdi et al.,
2013; Suh et al., 2014]. The studies all involved
cross-sectional analysis. A single measurement may
not be ideal for evaluating the correlations between
serum HBsAg titers and HBV DNA concentrations
because both may fluctuate over time [Chu et al.,
2002; Su et al., 2013]. Recently, a study showed that
the correlation between serum HBsAg titers and
HBV DNA concentrations differs between individuals
with wild type and mutated preS/S sequences. How-
ever, this study also was cross-sectional and it did
not address the correlation according to sequence
status of the BCP and preC region [Pollicino et al.,
2012]. In this study, we found that the correlation
between serum HBsAg titers and HBV DNA concen-
trations differs not only between individuals with
wild type and mutated preS/S sequences, but also
between individuals with wild type and mutated
BCP/preC sequences. Furthermore, these findings
were confirmed by longitudinal analysis and, there-
fore, the results are reliable.
HBsAg is one of the products of HBV replication
[Locarnini and Bowden, 2012]. Serum HBsAg titers
should correlate with HBV DNA levels. However, it
is possible for the association to be broken because
the inhibition of HBV DNA replication and HBV gene
expression occurs through independent mechanisms
[Guidotti et al., 1996]. It has been found that HBV
DNA declined rapidly during entecavir treatment
while the decline of serum HBsAg titer was slow
[Seto et al., 2014]. Most HBV mutations are subject
to selection forces from host immune surveillance,
antiviral therapy and replication fitness [Xu et al.,
2013]. Therefore, the appearance of mutations means
that HBV replication has encountered immune re-
sponses, which may influence the replication. In this
study, the viral loads of the mutant groups are
significantly lower than those of the wild type groups.
Therefore, it is possible that the association between
HBsAg production and HBV replication breaks down
in this case. If so, it is not difficult to understand
that there is no correlation between serum HBsAg
titer and HBV DNA concentrations in the mutant
groups.
Because of low cost and simplicity, many investi-
gators have tried to use HBsAg as a surrogate
marker of serum HBV DNA in chronic HBV infection
to predict the outcome of the infection and the
response to antiviral therapy. However, this approach
has not been used in clinical practice because it has
yielded contradicting results [Kuhns et al., 2004;
Ganji et al., 2011; Su et al., 2010; Sun et al., 2012].
Our findings suggest that HBsAg quantitation could
be used as a surrogate for viral load in wild-type
infections only. Therefore, the use of HBsAg titer as
a surrogate marker of serum HBV DNA has to take
into account the sequence status of the BCP and
PreC regions but not necessarily of PreS/S, which is
important to guide the use of HBsAg as a surrogate
for viral load. Considering the cost of sequencing,
HBsAg titration would be better not recommended as
a surrogate for viral load quantification in regions
where HBV genome sequencing is not easily
accessible.
The correlation between serum HBsAg titres and
HBV DNA concentrations between HBeAg positive
and negative individuals remains uncertain. Some
studies found this correlation in HBeAg-positive CHB
TABLE III. Simple and Multiple Linear Regression Analysis of Factors Associated With Serum HBsAg Levels
Variables
Unstandardized Coefficients Standardized Coefficients
t PB Std. Error Beta
Simple analysis DNA 0.278 0.036 0.642 7.668 0.000
HBeAg 1.148 0.154 0.631 7.464 0.000
Sex 0.120 0.179 0.073 0.672 0.503
Age 0.024 0.014 0.180 1.673 0.098
PreS/S 0.175 0.191 0.100 0.919 0.361
BCP 0.492 0.172 0.297 2.856 0.005
PreC 0.635 0.191 0.383 3.316 0.002
Genotypes 0.040 0.185 0.024 0.216 0.829
ALT 0.000 0.001 0.026 0.238 0.813
Multiple analysis HBeAg 0.752 0.251 0.413 2.999 0.004
Sex 0.393 0.157 0.237 2.501 0.015
DNA 0.145 0.063 0.316 2.311 0.024
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[Su et al., 2010; Sun et al., 2012; Suh et al., 2014]
while others found it in HBeAg-negative CHB [Chu
et al., 2002; Alghamdi et al., 2013]. The correlation
between serum HBsAg and HBV DNA concentrations
could be seen in both HBeAg-positive and negative
patients [Jang et al., 2013]. We obtained similar
results in this study. However, in our study no
correlation was found between serum HBsAg titer
and HBV DNA concentration in cases of the preC
termination mutation known to prevent the synthesis
of HBeAg. The association could be seen in only those
patients with wild type preC (data not shown). This
finding may help explain why some studies found the
correlation in HBeAg-negative individuals while
others did not.
Although various studies found that the HBsAg
titers correlated with HBV DNA in some phases of
chronic HBV infection [Antaki et al., 2012; Suh et al.,
2014], no such correlation was found in the four
phases in this study. Some studies suggested that
age and HBV DNA are the important parameters for
HBsAg [Jang et al., 2011; Matsumoto et al., 2012].
However, we found in this study that age is not
associated with the titer of HBsAg.
One of the important aims of HBsAg quantification
is to predict treatment outcome [Martinot-Peignoux
et al., 2013]. Our data here were obtained from
treatment-na€ve, asymptomatic carriers. We do not
know whether our findings may be replicated in those
undergoing antiviral therapy. In the future, we plan
to determine whether there is a correlation between
serum HBsAg and viral loads in patients undergoing
antiviral therapy.
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